XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.4
Share-Based Payments (Tables)
 6 Months Ended
Oct. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Allocation Of Share Based Compensation Expense
Stock-based compensation expense was recognized as follows (table in thousands):
 
Three Months Ended
October 31,		Six Months Ended
October 31,
 2024202320242023
General and administrative$(95)$31 $90 $215 
Sales and marketing51 21 91 87 
Research and development3 1 7 12 
Cost of oncology services50 — 79 162 
Total stock-based compensation expense$9 $53 $267 $476 
Schedule of Valuation Assumptions For Stock Options Black-Scholes assumptions used to calculate the fair value of options granted during the three and six months ended October 31, 2024 and 2023 were as follows:
 
Three Months Ended
October 31,		Six Months Ended
October 31,
 2024202320242023
Expected term in years
6
6
6
6
Risk-free interest rates
3.58% - 3.77%
4.49%
3.58% - 4.48%
3.95% - 4.49%
Volatility
59.47% - 59.57%
63.30%
59.47% - 62.72%
 62.83% - 63.30%
Dividend yield—%—%—%—%
Schedule of Stock Option Activity
The Company’s stock options activity for the six months ended October 31, 2024 was as follows:
 
Directors
and
Employees		Non-
Employees		TotalWeighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding, April 30, 20241,883,166 36,331 1,919,497 $5.04 5.2$2,172,000 
Granted102,500 — 102,500 4.26 9.8
Exercised(105,137)— (105,137)2.63 
Forfeited(210,750)— (210,750)6.50   
Canceled(500)— (500)6.11 
Expired(1,500)— (1,500)6.11   
Outstanding, October 31, 20241,667,779 36,331 1,704,110 4.96 4.8$1,275,000 
Vested and expected to vest as of October 31, 20241,667,779 36,331 1,704,110 4.96 4.8$1,275,000 
Exercisable as of October 31, 20241,566,097 3,750 1,569,847 4.94 4.4$1,275,000